VRAX Reports 88% Specificity, 92% PPV for ViraxImmune™ in Long COVID Trial, Targets $1.4B+ US Testing Market
Virax Biolabs Group Limited Ordinary Shares · Now $0.18
-35% in 3d after detection
Post-detection moves
1h
-4.1%
1d
-24%
3d
-35%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS